Meet Senzime at WSM in London, 10-12 January

Senzime will be exhibiting the TetraGraph in booth number 48, together with the distributor for UK and Ireland, Wardray Premise.

A workshop lead by Dr. Grant Rodney, Neuro-muscular junction (NMJ) monitoring, will be held during the meeting to highlight the value of neuromuscular monitoring in clinical practice, with particular focus on the benefits of quantitative monitoring. It will include practical demonstrations and display of current commercially available monitoring systems including the TetraGraph.

For further information, please contact:

Catrin Molund, Business Development Director
+46-708-11 69 11, 


About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime.